Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome. [Estudio randomizado, doble ciego, de 12 meses de duración con pregabalina en pacientes con síndrome de piernas inquietas.]

Trial Profile

Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome. [Estudio randomizado, doble ciego, de 12 meses de duración con pregabalina en pacientes con síndrome de piernas inquietas.]

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2014

At a glance

  • Drugs Pregabalin (Primary) ; Pramipexole
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Feb 2014 Results published in the New England Journal of Medicine.
    • 28 Apr 2012 Results presented at the 64th Annual Meeting of the American Academy of Neurology.
    • 16 Dec 2011 Primary endpoint 'International-Restless-Legs-Scale' has been met, according to a Pfizer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top